Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Payables (2016 - 2025)

iBio (IBIO) has disclosed Payables for 15 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 211.87% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.7 million, a 211.87% increase, with the full-year FY2025 number at $3.0 million, up 514.14% from a year prior.
  • Payables was $2.7 million for Q4 2025 at iBio, down from $3.5 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $27.0 million in Q3 2022 to a low of $481000.0 in Q2 2024.
  • A 5-year average of $8.7 million and a median of $3.2 million in 2025 define the central range for Payables.
  • Peak YoY movement for Payables: surged 1078.36% in 2022, then tumbled 96.75% in 2024.
  • iBio's Payables stood at $2.7 million in 2021, then soared by 630.67% to $20.0 million in 2022, then decreased by 27.48% to $14.5 million in 2023, then crashed by 94.14% to $851000.0 in 2024, then surged by 211.87% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Payables are $2.7 million (Q4 2025), $3.5 million (Q3 2025), and $3.0 million (Q2 2025).